Blog

Ultragenyx Expects 20 percent Revenue Growth in 2024 and Profitability in 2026

Posted on LinkedIn by CNBC Overtime, “The rare disease biotech company Ultragenyx says it expects 20 percent revenue growth in 2024 and profitability in 2026.

Ultragenyx founder and CEO Dr. Emil Kakkis joined us from the JPMorgan Chase & Co. Health Care conference to discuss the regulatory and approval challenges in developing and bringing a blockbuster drug for rare diseases to market, new therapies coming down the pipeline, and what the biotech company is doing to accelerate ‘good science into great medicine.'”

https://www.linkedin.com/posts/cnbc-overtime_the-rare-disease-biotech-company-ultragenyx-ugcPost-7151222163943907328-8-FR/?utm_source=share&utm_medium=member_android

Who We Are

Over thirty years ago, business leaders founded the North Bay Leadership Council on a simple premise: We can accomplish more by working together. Today, the Council includes 54 leading employers in the North Bay. Our members represent a wide variety of businesses, non-profits and educational institutions, with a workforce in excess of 25,000. As business and civic leaders, our goal is to promote sound public policy, innovation and sustainability to make our region a better place to live and work. For more information: Call 707.283.0028 / E-mail info@northbayleadership.org

Who We Are

www.northbayleadership.org